Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers
NCT07475182Phase 1Recruiting
- Sponsor
- Hainan Cancer Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-BCMA in malignant solid tumor, sponsored by Hainan Cancer Hospital. Primary endpoint: Adverse Events at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
CART-BCMA
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07475182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475182.